A Novel Sushi-IL15-PD1 CAR-NK92 Cell Line With Enhanced and PD-L1 Targeted Cytotoxicity Against Pancreatic Cancer Cells
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Novel Sushi-IL15-PD1 CAR-NK92 Cell Line With Enhanced and PD-L1 Targeted Cytotoxicity Against Pancreatic Cancer Cells
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-03-28
DOI
10.3389/fonc.2022.726985
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Retargeting of NK-92 Cells against High-Risk Rhabdomyosarcomas by Means of an ERBB2 (HER2/Neu)-Specific Chimeric Antigen Receptor
- (2021) Leonie D. H. Gossel et al. Cancers
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy
- (2020) Panagiotis Sarantis et al. World Journal of Gastrointestinal Oncology
- Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer
- (2020) Marcus Ruscetti et al. CELL
- Engineering Chimeric Antigen Receptor T cells Against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer
- (2020) Ching-Yao Yang et al. Molecular Therapy-Oncolytics
- PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations
- (2020) Kellsye P Fabian et al. Journal for ImmunoTherapy of Cancer
- T-cells “à la CAR-T(e)” - Genetically engineering T-cell response against cancer
- (2019) Vasyl Eisenberg et al. ADVANCED DRUG DELIVERY REVIEWS
- Prognostic value of PD-L1 expression in patients with pancreatic cancer
- (2019) Ying Hu et al. MEDICINE
- Remodeling of secretory lysosomes during education tunes functional potential in NK cells
- (2019) Jodie P. Goodridge et al. Nature Communications
- Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy
- (2019) Hyun Gul Yang et al. Journal for ImmunoTherapy of Cancer
- Meta‐analysis of recurrence pattern after resection for pancreatic cancer
- (2019) M. Tanaka et al. BRITISH JOURNAL OF SURGERY
- IFN-γ Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer
- (2019) Daisuke Imai et al. JOURNAL OF SURGICAL RESEARCH
- A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma
- (2019) Emilie Decaup et al. Frontiers in Immunology
- CAR-NK for tumor immunotherapy: Clinical transformation and future prospects
- (2019) Wenxiu Wang et al. CANCER LETTERS
- The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis
- (2018) He-Li Gao et al. Hepatobiliary & Pancreatic Diseases International
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- State-of-the-art strategies for targeting the DNA damage response in cancer
- (2018) Patrick G. Pilié et al. Nature Reviews Clinical Oncology
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD56bright NK cells exhibit potent antitumor responses following IL-15 priming
- (2017) Julia A. Wagner, Maximillian Rosario, Rizwan Romee, Melissa M. Berrien-Elliott, Stephanie E. Schneider, Jeffrey W. Leong, Ryan P. Sullivan, Brea A. Jewell, Michelle Becker-Hapak, Timothy Schappe, Sara Abdel-Latif, Aaron R. Ireland, Devika Jaishankar, Justin A. King, Ravi Vij, Dennis Clement, Jodie Goodridge, Karl-Johan Malmberg, Hing C. Wong, Todd A. Fehniger JOURNAL OF CLINICAL INVESTIGATION
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic value of PD-L1 overexpression for pancreatic cancer: evidence from a meta-analysis
- (2017) Yongxun Zhuan-Sun et al. OncoTargets and Therapy
- A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors
- (2016) Xiaojun Liu et al. CANCER RESEARCH
- The IL-15-Based ALT-803 Complex Enhances Fc RIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas
- (2015) M. Rosario et al. CLINICAL CANCER RESEARCH
- Induction of Split Anergy Conditions Natural Killer Cells to Promote Differentiation of Stem Cells through Cell–Cell Contact and Secreted Factors
- (2014) Han-Ching Tseng et al. Frontiers in Immunology
- Tumour–stroma interactions in pancreatic ductal adenocarcinoma: Rationale and current evidence for new therapeutic strategies
- (2013) V. Heinemann et al. CANCER TREATMENT REVIEWS
- Cytokine activation induces human memory-like NK cells
- (2012) R. Romee et al. BLOOD
- IL-15:IL-15 receptor alpha superagonist complex: High-level co-expression in recombinant mammalian cells, purification and characterization
- (2011) Kai-ping Han et al. CYTOKINE
- LFA-1 and CD2 Synergize for the Erk1/2 Activation in the Natural Killer (NK) Cell Immunological Synapse
- (2009) Xiaodong Zheng et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial
- (2008) S. Arai et al. CYTOTHERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now